


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/721,742
			Filing Date	November 26, 2003
			First Named Inventor	Masako NOZAKI
			Group Art Unit	1614
			Examiner Name	LESLIE A. RYDER
			Attorney Docket Number	NOZAKI=8.1A
Sheet	1	of	1	

[illegible]

Examiner Signature		Date Considered	09 MAY 2006
-----------------------	---	--------------------	-------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	NOT YET ASSIGNED 10/22/742
		Filing Date	ONE EVEN DATE HEREWITH 26 NOV 2003
		First Named Inventor	Masako NOZAKI
		Group Art Unit	1614
		Examiner Name	LESLIE A. POYDS
		Attorney Docket Number	NOZAKI=8.1A
Sheet 1	of 1		

[illegible]

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/721,742
Filing Date	November 26, 2003
First Named Inventor	Masako NOZAKI
Group Art Unit	1614
Examiner Name	LESUEA ROYDS
Attorney Docket Number	NOZAKI=8.1A

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
LAR	AD	US-2002/0123520 A1	09-05-2002	MARFAT et al.	—
LAR	AE	US-5,441,951	08-15-1995	SERHAN	—
LAR	AF	US-5,079,261	01-07-1992	SERHAN et al.	—

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code* Number* Kind Code ³ (if known)				
LAR	AG	EP 0905133 A1	03-31-1999	KOWA CO. LTD.	—	—
LAR	AH	EP 0528337 A1	02-24-1993	FUJISAWA PHARMACEUTICAL CO., LTD.	—	—
LAR	AI	EP 0351856 A2	01-24-1990	TAKEDA CHEMICAL INDUSTRIES, LTD.	—	—
LAR	AJ	EP 1424101 A2	06-02-2004	NOZAKI	—	—
LAR	AK	WO 99/21007	04-29-1999	PHARMAPRINT, INC.	—	—
LAR	AL	WO 02/060875 A1	08-08-2002	PFIZER PRODUCTORS INC.	—	—

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LAR	AM	ALVAREZ LOSADA, Role of platelet-activating factor, eicosanoids and bradykinin in adjuvant therapy for sepsis, <u>Acta Periatrica Espanola</u> , 60(9):535-544 (2002)	ABS
LAR	AN	BEERS AND BERKOW, Merck manual of diagnosis and therapy, <u>Merck Research Laboratories</u> , 1435-1437 (1999)	—
LAR	AO	KOBAYASHI et al., Effect of leukotriene antagonist on experimental delayed cerebral vasospasm, <u>Neurosurgery</u> , 31(3):550-556 (1992)	—
LAR	AP	MATSUO et al., Leukotriene B ₄ and C ₄ in cerebrospinal fluid from children with meningitis and febrile seizures, <u>Pediatric Neurology</u> , 14(2):121-124 (1996)	—
LAR	AQ	NEUWELT et al., Use of enhanced computerized tomography to evaluate osmotic blood-brain barrier disruption, <u>Neurosurgery</u> , 6(1):49-56 (1980)	—
LAR	AR	OGATA et al., Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice, <u>Infection and Immunity</u> , 60(6):2432-2437 (1992)	—
LAR	AS	YOSHIKAWA et al., Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in the rat: role of the leukocyte, <u>Circulatory Shock</u> , 38:29-33 (1992)	—
LAR	AT	Is there a therapeutic role for blood-brain barrier disruption? <u>Annals of Internal Medicine</u> , 93(1):137-139 (1980)	—
LAR	AU	Abstract- XP002284974 - <u>Derwent Publications Ltd.</u> , (1996)	—

Examiner
SignatureDate
Considered

09 MAY 2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.